Physician attitudes about genetic testing for localized prostate cancer

A national survey of radiation oncologists and urologists

Simon P. Kim, Neal J. Meropol, Cary P. Gross, Jon C. Tilburt, Badrinath Konety, James B. Yu, Robert Abouassaly, Christopher J. Weight, Stephen Williams, Nilay D. Shah

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    Introduction: Genetic testing has been recently put forth as a strategy to improve decision-making in the management of localized prostate cancer. Little is known about how frequently prostate cancer specialists are using these tests, or whether they consider them important or effective. We performed a national survey of radiation oncologists and urologists on their perceptions and self-reported use of genetic testing. Methods: From January to July 2017, a 4-wave mail survey was performed involving 915 radiation oncologists and 940 urologists about genetic testing and decision-making for localized prostate cancer. The survey queried the frequency and type of genetic test and the degree of importance and confidence of such tests. Pearson chi-square and multivariable logistic regression analyses were performed to identify respondent characteristics associated with outcomes. Results: Overall response rate was 37.3% (n = 691). One in six specialists reported frequently using genetic tests with urologists more likely than radiation oncologists to do so (26% vs. 4%; OR: 3.51, p < 0.001) and their perceived higher importance (46% vs. 20%; adjusted OR: 3.51, p < 0.001) as well as their confidence in doing so (70% vs. 39%; OR: 3.81, p < 0.001) for decision-making for localized prostate cancer. Prolaris and Oncotype represented the most commonly cited tumor-based genetic testings. Conclusions: Few radiation oncologists and urologists report frequently using genetic testing for treatment decision-making among patients diagnosed with localized prostate cancer, though more urologists use these tests and believe they yield meaningful results.

    Original languageEnglish (US)
    JournalUrologic Oncology: Seminars and Original Investigations
    DOIs
    StateAccepted/In press - Jan 1 2018

    Fingerprint

    Genetic Testing
    Prostatic Neoplasms
    Physicians
    Decision Making
    Postal Service
    Logistic Models
    Regression Analysis
    Radiation Oncologists
    Urologists
    Surveys and Questionnaires
    Neoplasms

    Keywords

    • Biomarkers
    • Genetic testing
    • Genomics
    • Overtreatment
    • Prostate cancer
    • Survey
    • Treatment recommendations

    ASJC Scopus subject areas

    • Oncology
    • Urology

    Cite this

    Physician attitudes about genetic testing for localized prostate cancer : A national survey of radiation oncologists and urologists. / Kim, Simon P.; Meropol, Neal J.; Gross, Cary P.; Tilburt, Jon C.; Konety, Badrinath; Yu, James B.; Abouassaly, Robert; Weight, Christopher J.; Williams, Stephen; Shah, Nilay D.

    In: Urologic Oncology: Seminars and Original Investigations, 01.01.2018.

    Research output: Contribution to journalArticle

    Kim, Simon P. ; Meropol, Neal J. ; Gross, Cary P. ; Tilburt, Jon C. ; Konety, Badrinath ; Yu, James B. ; Abouassaly, Robert ; Weight, Christopher J. ; Williams, Stephen ; Shah, Nilay D. / Physician attitudes about genetic testing for localized prostate cancer : A national survey of radiation oncologists and urologists. In: Urologic Oncology: Seminars and Original Investigations. 2018.
    @article{301902a13b3242679c7154c1462a4c03,
    title = "Physician attitudes about genetic testing for localized prostate cancer: A national survey of radiation oncologists and urologists",
    abstract = "Introduction: Genetic testing has been recently put forth as a strategy to improve decision-making in the management of localized prostate cancer. Little is known about how frequently prostate cancer specialists are using these tests, or whether they consider them important or effective. We performed a national survey of radiation oncologists and urologists on their perceptions and self-reported use of genetic testing. Methods: From January to July 2017, a 4-wave mail survey was performed involving 915 radiation oncologists and 940 urologists about genetic testing and decision-making for localized prostate cancer. The survey queried the frequency and type of genetic test and the degree of importance and confidence of such tests. Pearson chi-square and multivariable logistic regression analyses were performed to identify respondent characteristics associated with outcomes. Results: Overall response rate was 37.3{\%} (n = 691). One in six specialists reported frequently using genetic tests with urologists more likely than radiation oncologists to do so (26{\%} vs. 4{\%}; OR: 3.51, p < 0.001) and their perceived higher importance (46{\%} vs. 20{\%}; adjusted OR: 3.51, p < 0.001) as well as their confidence in doing so (70{\%} vs. 39{\%}; OR: 3.81, p < 0.001) for decision-making for localized prostate cancer. Prolaris and Oncotype represented the most commonly cited tumor-based genetic testings. Conclusions: Few radiation oncologists and urologists report frequently using genetic testing for treatment decision-making among patients diagnosed with localized prostate cancer, though more urologists use these tests and believe they yield meaningful results.",
    keywords = "Biomarkers, Genetic testing, Genomics, Overtreatment, Prostate cancer, Survey, Treatment recommendations",
    author = "Kim, {Simon P.} and Meropol, {Neal J.} and Gross, {Cary P.} and Tilburt, {Jon C.} and Badrinath Konety and Yu, {James B.} and Robert Abouassaly and Weight, {Christopher J.} and Stephen Williams and Shah, {Nilay D.}",
    year = "2018",
    month = "1",
    day = "1",
    doi = "10.1016/j.urolonc.2018.07.002",
    language = "English (US)",
    journal = "Urologic Oncology",
    issn = "1078-1439",
    publisher = "Elsevier Inc.",

    }

    TY - JOUR

    T1 - Physician attitudes about genetic testing for localized prostate cancer

    T2 - A national survey of radiation oncologists and urologists

    AU - Kim, Simon P.

    AU - Meropol, Neal J.

    AU - Gross, Cary P.

    AU - Tilburt, Jon C.

    AU - Konety, Badrinath

    AU - Yu, James B.

    AU - Abouassaly, Robert

    AU - Weight, Christopher J.

    AU - Williams, Stephen

    AU - Shah, Nilay D.

    PY - 2018/1/1

    Y1 - 2018/1/1

    N2 - Introduction: Genetic testing has been recently put forth as a strategy to improve decision-making in the management of localized prostate cancer. Little is known about how frequently prostate cancer specialists are using these tests, or whether they consider them important or effective. We performed a national survey of radiation oncologists and urologists on their perceptions and self-reported use of genetic testing. Methods: From January to July 2017, a 4-wave mail survey was performed involving 915 radiation oncologists and 940 urologists about genetic testing and decision-making for localized prostate cancer. The survey queried the frequency and type of genetic test and the degree of importance and confidence of such tests. Pearson chi-square and multivariable logistic regression analyses were performed to identify respondent characteristics associated with outcomes. Results: Overall response rate was 37.3% (n = 691). One in six specialists reported frequently using genetic tests with urologists more likely than radiation oncologists to do so (26% vs. 4%; OR: 3.51, p < 0.001) and their perceived higher importance (46% vs. 20%; adjusted OR: 3.51, p < 0.001) as well as their confidence in doing so (70% vs. 39%; OR: 3.81, p < 0.001) for decision-making for localized prostate cancer. Prolaris and Oncotype represented the most commonly cited tumor-based genetic testings. Conclusions: Few radiation oncologists and urologists report frequently using genetic testing for treatment decision-making among patients diagnosed with localized prostate cancer, though more urologists use these tests and believe they yield meaningful results.

    AB - Introduction: Genetic testing has been recently put forth as a strategy to improve decision-making in the management of localized prostate cancer. Little is known about how frequently prostate cancer specialists are using these tests, or whether they consider them important or effective. We performed a national survey of radiation oncologists and urologists on their perceptions and self-reported use of genetic testing. Methods: From January to July 2017, a 4-wave mail survey was performed involving 915 radiation oncologists and 940 urologists about genetic testing and decision-making for localized prostate cancer. The survey queried the frequency and type of genetic test and the degree of importance and confidence of such tests. Pearson chi-square and multivariable logistic regression analyses were performed to identify respondent characteristics associated with outcomes. Results: Overall response rate was 37.3% (n = 691). One in six specialists reported frequently using genetic tests with urologists more likely than radiation oncologists to do so (26% vs. 4%; OR: 3.51, p < 0.001) and their perceived higher importance (46% vs. 20%; adjusted OR: 3.51, p < 0.001) as well as their confidence in doing so (70% vs. 39%; OR: 3.81, p < 0.001) for decision-making for localized prostate cancer. Prolaris and Oncotype represented the most commonly cited tumor-based genetic testings. Conclusions: Few radiation oncologists and urologists report frequently using genetic testing for treatment decision-making among patients diagnosed with localized prostate cancer, though more urologists use these tests and believe they yield meaningful results.

    KW - Biomarkers

    KW - Genetic testing

    KW - Genomics

    KW - Overtreatment

    KW - Prostate cancer

    KW - Survey

    KW - Treatment recommendations

    UR - http://www.scopus.com/inward/record.url?scp=85053062861&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85053062861&partnerID=8YFLogxK

    U2 - 10.1016/j.urolonc.2018.07.002

    DO - 10.1016/j.urolonc.2018.07.002

    M3 - Article

    JO - Urologic Oncology

    JF - Urologic Oncology

    SN - 1078-1439

    ER -